艾美疫苗提交无血清狂犬疫苗上市申请
财中社11月17日电艾美疫苗（06660）发布公告，通知股东及潜在投资者其最新业务进展。公司已向国家药品监督管理局提交无血清迭代狂犬疫苗的上市注册预申请。根据已完成的III期临床研究结果，该疫苗显示出良好的安全性、免疫原性和免疫持久性，达到了临床预设目标。
目前，全球市场尚未有无血清狂犬疫苗获批上市，公司的产品有望成为首个上市的无血清狂犬疫苗。与传统的有血清狂犬疫苗相比，该疫苗不含动物血清，显著提高了安全性，降低了不良反应的概率。公司已完成满足国际标准的生产车间建设，并具备规模化生产能力，致力于推动全球狂犬疫苗技术的迭代升级。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10